

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

January 8, 2021

Steve White Chief Executive Officer Harvest Health & Recreation Inc. 1155 W. Rio Salado Parkway Suite 201 Tempe, AZ 85281

Re: Harvest Health & Recreation Inc.
Amendment No. 1 to Registration Statement on Form 10-12G
Filed December 21, 2020
File No. 000-56224

Dear Mr. White:

We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

Amendment No. 1 to Registration Statement on Form 10-12G filed December 21, 2020

Management's Discussion and Analysis of Financial Condition and Results of Operations Year Ended December 31, 2018 Compared to Year Ended December 31, 2017 Total Expenses, page 67

1. Please revise to present more details of the \$2.9 million expense due to a fraudulent wire transaction, and explain to us how this impacted internal controls discussed on page 52.

ITEM 6. EXECUTIVE COMPENSATION, page 88

2. We note that this filing will become effective by operation of law after the end of your fiscal year ended December 31, 2020. Please update your filing to include updated executive compensation disclosure pursuant to Item 402 of Regulation S-K for the fiscal year ended December 31, 2020.

Steve White Harvest Health & Recreation Inc. January 8, 2021 Page 2

<u>Interim Unaudited Condensed Consolidatesd Financial Statements</u> Note 16. Fair Value and Risk Management, page F-23

3. We note your response to comment 22 and the revisions on pages F-25 and F-36. However, the revised disclosures of the significant assumptions you used to estimate fair value of contingent consideration and the warrant liability are vague. Please revise to provide disclosures of the specific significant assumptions used in your valuation.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

You may contact Jeanne Bennett at 202-551-3606 or Terence O'Brien at 202-551-3355 if you have questions regarding comments on the financial statements and related matters. Please contact Jeffrey Gabor at 202-551-2544 or Mary Beth Breslin at 202-551-3625 with any other questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Thomas M. Rose, Esq.